IRIS
GORI SAVELLINI, GIANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.076
EU - Europa 3.423
AS - Asia 1.649
SA - Sud America 385
AF - Africa 58
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 1
Totale 9.599
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.027
RU - Federazione Russa 966
IE - Irlanda 595
SG - Singapore 579
CN - Cina 533
IT - Italia 484
GB - Regno Unito 369
BR - Brasile 328
SE - Svezia 234
DE - Germania 192
UA - Ucraina 164
HK - Hong Kong 159
FR - Francia 146
FI - Finlandia 136
VN - Vietnam 109
KR - Corea 100
IN - India 41
PL - Polonia 27
CA - Canada 26
AR - Argentina 25
CI - Costa d'Avorio 25
ES - Italia 23
NL - Olanda 23
IQ - Iraq 19
BD - Bangladesh 18
JP - Giappone 17
MX - Messico 16
AT - Austria 15
TR - Turchia 14
CZ - Repubblica Ceca 13
ZA - Sudafrica 13
ID - Indonesia 11
EC - Ecuador 10
BE - Belgio 7
CO - Colombia 7
EU - Europa 7
MA - Marocco 5
PK - Pakistan 5
SA - Arabia Saudita 5
CH - Svizzera 4
DZ - Algeria 4
IL - Israele 4
PY - Paraguay 4
UZ - Uzbekistan 4
IR - Iran 3
LT - Lituania 3
LU - Lussemburgo 3
PE - Perù 3
TH - Thailandia 3
TN - Tunisia 3
UY - Uruguay 3
AL - Albania 2
BG - Bulgaria 2
CL - Cile 2
DO - Repubblica Dominicana 2
EG - Egitto 2
GE - Georgia 2
HU - Ungheria 2
IM - Isola di Man 2
KZ - Kazakistan 2
LB - Libano 2
LY - Libia 2
NP - Nepal 2
PA - Panama 2
PH - Filippine 2
PT - Portogallo 2
QA - Qatar 2
RO - Romania 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
AO - Angola 1
AU - Australia 1
BO - Bolivia 1
BY - Bielorussia 1
BZ - Belize 1
CR - Costa Rica 1
CY - Cipro 1
EE - Estonia 1
ET - Etiopia 1
GI - Gibilterra 1
GR - Grecia 1
HR - Croazia 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MY - Malesia 1
NO - Norvegia 1
OM - Oman 1
PS - Palestinian Territory 1
RS - Serbia 1
SY - Repubblica araba siriana 1
TG - Togo 1
YE - Yemen 1
Totale 9.599
Salva come PNG Salva come JPEG
Città #
Dublin 578
Dallas 490
Fairfield 396
Ashburn 348
Chandler 303
Singapore 301
Moscow 280
Southend 275
Santa Clara 258
Woodbridge 223
Seattle 180
Wilmington 170
Siena 162
Beijing 158
Hong Kong 157
Cambridge 146
Houston 134
Jacksonville 128
Princeton 105
Seoul 98
Hefei 91
Ann Arbor 90
Helsinki 79
New York 65
Munich 63
Los Angeles 62
Milan 55
Menlo Park 40
Nanjing 38
Fremont 36
Ho Chi Minh City 35
Rome 35
The Dalles 32
São Paulo 29
Buffalo 27
Florence 27
Warsaw 26
Abidjan 25
Boardman 24
San Diego 22
Hanoi 21
Redondo Beach 21
San Mateo 18
Montreal 15
Shanghai 15
Chicago 14
Dong Ket 14
London 14
Nanchang 14
Norwalk 14
Turku 14
Bengaluru 13
Council Bluffs 13
Lancaster 13
Tokyo 13
Lappeenranta 12
Lauterbourg 12
Rio de Janeiro 12
Columbus 11
Hebei 11
Shenyang 11
Düsseldorf 10
Málaga 10
Vienna 10
Atlanta 9
Chennai 9
Denver 9
Frankfurt am Main 9
Portsmouth 9
Tianjin 9
Brooklyn 8
Manchester 8
Nuremberg 8
San Francisco 8
Venezia 8
Brussels 7
Kunming 7
Poplar 7
Baghdad 6
Belo Horizonte 6
Guangzhou 6
Johannesburg 6
Olomouc 6
Phoenix 6
Charlotte 5
Goiânia 5
Guarulhos 5
Jakarta 5
North Bergen 5
Orem 5
Poli 5
Porto Alegre 5
Amsterdam 4
Brno 4
Changsha 4
Durban 4
Erbil 4
Espoo 4
Haiphong 4
Hounslow 4
Totale 6.339
Salva come PNG Salva come JPEG
Nome #
A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease 349
Anti-angiogenetic effects of immune-reconstituted influenza virosomes assembled with parathyroid hormone-related protein derived peptide vaccine. 330
Immunization with Toscana virus N-Gc proteins protects mice against virus challenge 249
Antibody response to SARS-CoV-2 in infected patients with different clinical outcome 243
5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine 233
Cetuximab +/- chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro 227
Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. 226
Comparison of a new prototype immunochromatographic assay and a commercial enzyme-linked immunosorbent assay for the detection of serum antibodies against Toscana virus 209
Immunosuppressive monoclonal antibody to CD64 from patients with long-term stable multiple sclerosis 208
Diagnostic tools for Toscana virus infection 202
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine 200
Retrospective diagnosis of West Nile virus infection in a patient with meningoencephalitis in Tuscany, Italy 197
Efficient delivery of DNA to dendritic cells mediated by influenza virosomes 195
Toscana virus induces interferon although its NSs protein reveals antagonistic activity. 191
Identification of a neutralizing epitope on tosv gn glycoprotein 188
Seroprevalence to measles virus after vaccination or natural infection in an adult population, in Italy 186
Seroprevalence of antibodies to Sandfly fever Sicilian virus in a sample population in Tuscany, Italy 181
Evaluation of a novel immunogenic vaccine platform based on a genome replication-deficient Sendai vector 179
Development of a mouse model for the study of Toscana virus pathogenesis 177
Toscana Virus NSs protein inhibits the induction of type I interferon by interacting with RIG-I. 176
Immune-reconstituted influenza virosome containing CD40L gene enhances the immunological and protective activity of a carcinoembryonic antigen anticancer vaccine 172
Omicron infection evokes cross-protection against SARS-CoV-2 variants in vaccinees 165
Detection of asymptomatic SARS-CoV-2 infections among healthcare workers: Results from a large-scale screening program based on rapid serological testing 163
Nucleotide variability of Toscana virus M segment in strains isolated from clinical cases 162
Immunological characterization of Respiratory Syncytial Virus N protein epitopes recognized by human cytotoxic T lymphocytes 162
SARS-CoV-2 Antibody Response in Persons with Past Natural Infection 161
Toscana virus non-structural protein NSs acts as E3 ubiquitin ligase promoting RIG-I degradation 157
Ubiquitin and not only unfolded domains drives toscana virus non-structural NSs protein degradation 155
Human Polymorphonuclear Cells Support Zika Virus to Cross Endothelial Monolayer and Access Bloodstream 153
Infectious Toscana virus in seminal fluid of young man returning from Elba Island, Italy 152
Neutralizing antibody response of vaccinees to SARS-CoV-2 variants 151
Efficient inactivation of sars-cov-2 and other rna or dna viruses with blue led light 149
Comparative performance of a new sars-cov-2 rapid detection system 149
Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID 145
Hepatitis C Virus Core Antigen (HCVAg): an affordable assay to monitor the efficacy of treatment in DAAs era 145
How long can SARS-CoV-2 persist in human corpses? 144
Epidemiology of Toscana virus in South Tuscany over the years 2011-2019 139
Immunoglobulin M seropositivity for Toscana virus in a random population sample in Sicily 134
A novel replication deficient paramyxovirus elicits strong virus neutralising antibody and T cell responses in mice. 134
Deletion of 82–85 N-Terminal Residues in SARS-CoV-2 Nsp1 Restricts Virus Replication 130
Serological and molecular detection of Toscana and other Phleboviruses in patients and sandflies in Tunisia 130
Toscana virus infects dendritic and endothelial cells opening the way for the central nervous system 128
Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience 124
Dysregulation of intracellular redox homeostasis by the SARS-CoV-2 ORF6 protein 118
Development of a vaccine against hRSV and hPIV3 using a replication deficient Sendai virus vector. 118
Antibody Response against Circulating Omicron Variants 8 Months after the Third Dose of mRNA Vaccine 115
CD40L gene assembled to Immune-Reconstituted Influenza Virosome (IRIV) enhances the immunological and protective activity of a CEA anti-cancer vaccine. 111
Nucleopore Traffic Is Hindered by SARS-CoV-2 ORF6 Protein to Efficiently Suppress IFN-β and IL-6 Secretion 110
Degradation of RIG-I and inhibition of IFN-beta induction by Toscana Virus NSs protein. 110
Seronegative Vaccinees May Not Benefit From Multiple Booster Doses of MMR Vaccine in Restoring Immunity 104
null 103
SARS-CoV-2 omicron sub-lineages differentially modulate interferon response in human lung epithelial cells 101
Development of a vaccine against Toscana Virus. 101
null 94
null 94
Toscana virus epidemiology: from Italy to beyond. 89
SARS-CoV-2 n protein targets TRIM25-mediated RIG-I activation to suppress innate immunity 81
Seroprevalence and risk factors for Toscana and Sicilian Virus infection in a sample population of Sicily (Italy). 78
Truncation of the C-terminal region of Toscana Virus NSs protein is critical for interferon-β antagonism and protein stability 74
In vivo study of the PTH-rP DNA/IRIV vaccine for immune response into humanized transgenic mouse. 67
RIG-I-mediated antiviral signalling is inhibited by toscana virus NSs protein. 66
Toscana virus induces IFN-β production by activation of the cellular sensor RIG-I. 61
In vivo study of the PTH-rP DNA/IRIV vaccine for immune response into humanized transgenic mouse. 57
Prevalence of Toscana and Sicilian phlebovirus antibodies in classic Kaposi’s sarcoma cases and control subjects in Sicily 55
RECOGNITION OF TOSCANA VIRUS NSs REGIONS INVOLVED IN RIG-I DEGRADATION AND IFN-b INHIBITION 54
null 41
Totale 9.752
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.034
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 34.034
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021600 0 0 0 0 0 185 71 89 76 47 61 71
2021/2022613 34 49 22 30 23 18 32 51 69 55 68 162
2022/20231.036 59 107 135 122 111 224 16 93 100 22 34 13
2023/2024950 29 50 74 73 36 222 341 17 7 12 13 76
2024/20251.933 70 98 177 109 246 129 136 100 210 76 200 382
2025/20262.776 339 576 424 578 830 29 0 0 0 0 0 0
Totale 9.752